Variation in Trans-3′-Hydroxycotinine Glucuronidation Does Not Alter the Nicotine Metabolite Ratio or Nicotine Intake

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Zhu, Andy Z X ^a   Zhou, Qian ^a   Cox, Lisa Sanderson ^b   Ahluwalia, Jasjit S ^c   Benowitz, Neal L ^d   Tyndale, Rachel F ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3' HYDROXYCOTININE; CYTOCHROME P450 2A6; NICOTINE;

ADULT; ARTICLE; CHEMICAL PARAMETERS; CLINICAL INDICATOR; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENOTYPE; GLUCURONIDATION; HUMAN; IN VIVO STUDY; MALE; METABOLISM; MUTATOR GENE; NICOTINE INTAKE; NICOTINE METABOLITE RATIO; NICOTINE METABOLSIM; PHENOTYPE; PREDICTION; SMOKING; UGT2B10 GENE; UGT2B17 GENE;

ADOLESCENT; ADULT; AFRICAN AMERICANS; ARYL HYDROCARBON HYDROXYLASES; BIOLOGICAL MARKERS; COTININE; FEMALE; GENE DELETION; GENOTYPE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; MALE; MIDDLE AGED; NICOTINE; SMOKING; YOUNG ADULT;

EID: 84880970493     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070938     Document Type: Article

References (38)

1. Benowitz NL, Jacob P 3rd (1985) Nicotine renal excretion rate influences nicotine intake during cigarette smoking. J Pharmacol Exp Ther 234: 153-155.
2. Benowitz NL, Perez-Stable EJ, Herrera B, Jacob P 3rd (2002) Slower metabolism and reduced intake of nicotine from cigarette smoking in Chinese-Americans. J Natl Cancer Inst 94: 108-115.
3. Pianezza ML, Sellers EM, Tyndale RF, (1998) Nicotine metabolism defect reduces smoking. Nature 393: 750.
4. Messina ES, Tyndale RF, Sellers EM, (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282: 1608-1614.
5. Benowitz NL, Jacob P 3rd (1994) Metabolism of nicotine to cotinine studied by a dual stable isotope method. Clin Pharmacol Ther 56: 483-493.
6. Nakajima M, Yamamoto T, Nunoya K, Yokoi T, Nagashima K, et al. (1996) Characterization of CYP2A6 involved in 3′-hydroxylation of cotinine in human liver microsomes. J Pharmacol Exp Ther 277: 1010-1015.
7. Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, et al. (2013) The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiol Biomarkers Prev 22: 708-718.
8. Hukkanen J, Jacob P 3rd, Benowitz NL (2005) Metabolism and disposition kinetics of nicotine. Pharmacol Rev 57: 79-115.
9. Zhu AZX, Tyndale RF (2012) Nicotine Metabolism and its Implications. Metabolism of Drugs and Other Xenobiotics: Wiley-VCH Verlag GmbH & Co. KGaA. 465-492.
10. Dempsey D, Tutka P, Jacob P 3rd, Allen F, Schoedel K, et al (2004) Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clin Pharmacol Ther 76: 64-72.
11. Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, et al. (2013) Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis 34: 93-101.
12. Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, et al. (2008) Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clin Pharmacol Ther 84: 320-325.
13. Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, et al. (2009) Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther 85: 635-643.
14. Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, et al. (2006) Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation. Clin Pharmacol Ther 79: 600-608.
15. Benowitz NL, Kuyt F, Jacob P 3rd, Jones RT, Osman AL (1983) Cotinine disposition and effects. Clinical pharmacology and therapeutics 34: 604-611.
16. Benowitz NL, Jacob P 3rd (2001) Trans-3′-hydroxycotinine: disposition kinetics, effects and plasma levels during cigarette smoking. Br J Clin Pharmacol 51: 53-59.
17. Lea RA, Dickson S, Benowitz NL, (2006) Within-subject variation of the salivary 3HC/COT ratio in regular daily smokers: prospects for estimating CYP2A6 enzyme activity in large-scale surveys of nicotine metabolic rate. J Anal Toxicol 30: 386-389.
18. St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, et al (2012) Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiol Biomarkers Prev 21: 1105-1114.
19. Chen G, Giambrone NE, Lazarus P, (2012) Glucuronidation of trans-3′-hydroxycotinine by UGT2B17 and UGT2B10. Pharmacogenet Genomics 22: 183-190.
20. Xue Y, Sun D, Daly A, Yang F, Zhou X, et al. (2008) Adaptive evolution of UGT2B17 copy-number variation. American journal of human genetics 83: 337-346.
21. Yang TL, Chen XD, Guo Y, Lei SF, Wang JT, et al. (2008) Genome-wide copy-number-variation study identified a susceptibility gene, UGT2B17, for osteoporosis. American journal of human genetics 83: 663-674.
22. Chen G, Giambrone NE Jr, Dluzen DF, Muscat JE, Berg A, et al. (2010) Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer research 70: 7543-7552.
23. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D, (2005) Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenetics and genomics 15: 769-778.
24. Binnington JM, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, et al. (2012) CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenet Genomics 22: 429-440.
25. Kuehl GE, Murphy SE, (2003) N-glucuronidation of trans-3′-hydroxycotinine by human liver microsomes. Chem Res Toxicol 16: 1502-1506.
26. Yamanaka H, Nakajima M, Katoh M, Kanoh A, Tamura O, et al. (2005) Trans-3′-hydroxycotinine O- and N-glucuronidations in human liver microsomes. Drug Metab Dispos 33: 23-30.
27. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P, (2007) Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 Codon 67 (Asp>Tyr) polymorphism. Cancer Res 67: 9024-9029.
28. Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE, (2010) Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Ther 332: 202-209.
29. Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, et al. (2012) Bupropion for smoking cessation in African American light smokers: A randomized controlled trial. Journal of the National Cancer Institute 104: 1-9.
30. Benowitz NL, Dains KM, Dempsey D, Wilson M, Jacob P, (2011) Racial differences in the relationship between number of cigarettes smoked and nicotine and carcinogen exposure. Nicotine Tob Res 13: 772-783.
31. Benowitz NL, Jacob P 3rd, Fong I, Gupta S (1994) Nicotine metabolic profile in man: comparison of cigarette smoking and transdermal nicotine. J Pharmacol Exp Ther 268: 296-303.
32. Benowitz NL, Dains KM, Dempsey D, Havel C, Wilson M, et al. (2010) Urine menthol as a biomarker of mentholated cigarette smoking. Cancer Epidemiol Biomarkers Prev 19: 3013-3019.
33. Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, et al. (2009) Genetic and environmental influences on the ratio of 3′hydroxycotinine to cotinine in plasma and urine. Pharmacogenet Genomics 19: 388-398.
34. Derby KS, Cuthrell K, Caberto C, Carmella SG, Franke AA, et al. (2008) Nicotine metabolism in three ethnic/racial groups with different risks of lung cancer. Cancer Epidemiol Biomarkers Prev 17: 3526-3535.
35. Yamanaka H, Nakajima M, Fukami T, Sakai H, Nakamura A, et al. (2005) CYP2A6 AND CYP2B6 are involved in nornicotine formation from nicotine in humans: interindividual differences in these contributions. Drug Metab Dispos 33: 1811-1818.
36. Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, et al. (2010) Genetic Variation in Nicotine Metabolism Predicts the Efficacy of Extended-Duration Transdermal Nicotine Therapy. Clin Pharmacol Ther 87: 553-557.
37. Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C, (2007) An association of CYP2A6 genotype and smoking topography. Nicotine Tob Res 9: 511-518.
38. Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, et al. (2011) Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiol Biomarkers Prev 20: 234-238.